Certara (NASDAQ:CERT) Shares Down 3.4% – Time to Sell?

Certara, Inc. (NASDAQ:CERT)’s share price dropped 3.4% on Tuesday . The stock traded as low as $10.60 and last traded at $10.60. Approximately 19,359 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 769,666 shares. The stock had previously closed at $10.97.

Analysts Set New Price Targets

A number of analysts have issued reports on CERT shares. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Friday, September 27th. Barclays reduced their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Finally, Robert W. Baird dropped their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $15.92.

Certara Price Performance

The firm has a market capitalization of $1.89 billion, a P/E ratio of -58.80, a PEG ratio of 4.55 and a beta of 1.52. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $10.88 and its 200-day moving average is $11.95.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same quarter last year, the company posted $0.06 EPS. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. As a group, sell-side analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Brown Brothers Harriman & Co. bought a new stake in shares of Certara during the 3rd quarter valued at approximately $27,292,000. Wasatch Advisors LP lifted its stake in Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after purchasing an additional 1,651,076 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after buying an additional 1,128,006 shares in the last quarter. Daventry Group LP grew its stake in shares of Certara by 153.0% during the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after buying an additional 791,405 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in shares of Certara by 78.6% during the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock worth $14,123,000 after buying an additional 530,598 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.